Biogen/$BIIB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Biogen
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
Ticker
$BIIB
Sector
Primary listing
Employees
7,605
Headquarters
Website
Biogen Metrics
BasicAdvanced
$20B
13.31
$10.45
0.14
-
Price and volume
Market cap
$20B
Beta
0.14
52-week high
$206.76
52-week low
$110.04
Average daily volume
1.4M
Financial strength
Current ratio
2.503
Quick ratio
1.521
Long term debt to equity
37.397
Total debt to equity
37.397
Interest coverage (TTM)
9.82%
Profitability
EBITDA (TTM)
3,222.4
Gross margin (TTM)
75.58%
Net profit margin (TTM)
15.31%
Operating margin (TTM)
24.79%
Effective tax rate (TTM)
14.86%
Revenue per employee (TTM)
$1,310,000
Management effectiveness
Return on assets (TTM)
5.62%
Return on equity (TTM)
9.13%
Valuation
Price to earnings (TTM)
13.308
Price to revenue (TTM)
2.032
Price to book
1.16
Price to tangible book (TTM)
12.19
Price to free cash flow (TTM)
11.089
Free cash flow yield (TTM)
9.02%
Free cash flow per share (TTM)
12.546
Growth
Revenue change (TTM)
3.36%
Earnings per share change (TTM)
31.67%
3-year revenue growth (CAGR)
-2.04%
10-year revenue growth (CAGR)
-0.30%
3-year earnings per share growth (CAGR)
-9.19%
10-year earnings per share growth (CAGR)
-3.39%
What the Analysts think about Biogen
Analyst ratings (Buy, Hold, Sell) for Biogen stock.
Biogen Financial Performance
Revenues and expenses
Biogen Earnings Performance
Company profitability
Biogen News
AllArticlesVideos

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
CNBC Television·3 weeks ago

Biogen raises annual profit forecast on strong demand for rare disease drugs
Reuters·3 weeks ago

Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study finds
Reuters·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Biogen stock?
Biogen (BIIB) has a market cap of $20B as of August 22, 2025.
What is the P/E ratio for Biogen stock?
The price to earnings (P/E) ratio for Biogen (BIIB) stock is 13.31 as of August 22, 2025.
Does Biogen stock pay dividends?
No, Biogen (BIIB) stock does not pay dividends to its shareholders as of August 22, 2025.
When is the next Biogen dividend payment date?
Biogen (BIIB) stock does not pay dividends to its shareholders.
What is the beta indicator for Biogen?
Biogen (BIIB) has a beta rating of 0.14. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.